Antiobesity carbonic anhydrase inhibitors: A literature and patent review

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 6, 2013, Pages 725-735

  Scozzafava, Andrea ^a   Supuran, Claudiu T ^a   Carta, Fabrizio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Carbonic anhydrase inhibitors; Obesity; Topiramate; Zonisamide

Indexed keywords

ANTIOBESITY AGENT; CARBONATE DEHYDRATASE INHIBITOR; PHENTERMINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; ZONISAMIDE;

ARCUATE NUCLEUS; BONE REMODELING; CALORIC INTAKE; CELLULAR DISTRIBUTION; ELECTROLYTE TRANSPORT; ENERGY CONVERSION; ENERGY EXPENDITURE; FATTY ACID METABOLISM; GABAERGIC TRANSMISSION; GLUCONEOGENESIS; HUMAN; HYDROGEN BOND; LIPOGENESIS; LOW CALORY DIET; METABOLIC REGULATION; NUCLEOPHILICITY; OBESITY; PATENT; REVIEW; SEDENTARY LIFESTYLE; STOMACH BYPASS; SUBSTITUTION REACTION; TISSUE DISTRIBUTION; TISSUE SPECIFICITY; UREA CYCLE; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; ANTI-OBESITY AGENTS; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; DRUG DESIGN; FRUCTOSE; HUMANS; ISOXAZOLES; LIPOGENESIS; MITOCHONDRIA; MOLECULAR TARGETED THERAPY; OBESITY; PATENTS AS TOPIC;

EID: 84878062801     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.790957     Document Type: Review

References (97)

1. Available from: http://www.who.int/topics/obesity/en
2. Kelner K, Helmuth L. Obesity-What is to be done? Science 2003;299:845
3. Hill OJ, Wyatt HR, Reed GW, Peters JC. Obesity and the environment: where do we go from here? Science 2003;299:853-5
4. Available from: http://www.cdc.gov/nchs/products/hestats.htm
5. Ebbeling CB, Feldman HA, Chomitz VR, et al. A randomized trial of sugar-sweetened beverages and adolescent body weight. New Engl J Med 2012;367:1407-16
6. Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin Ther Pat 2000;10:575-600
7. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nature Rev Drug Discov 2008;7:168-81
8. Supuran CT. Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity. Expert Opin Ther Pat 2003;13:1545-50
9. Ioannides-Demos LL, Proietto J, Tonkin AM, McNeil JJ. Safety of drug therapies used for weight loss and treatment of obesity. Drug Saf 2006;29:277-302
10. Sunyer-Pi X. A clinical view f the obesity problem. Science 2003;299:859-60
11. Gura T. Obesity drug pipeline not so fat. Science 2003;299:849-52
12. Little TJ, Horowitz M, Feinle-Bisset C. Role of cholecystokinin in appetite control and body weight regulation. Obese Rev 2005;6:297-306
13. Kirchner H, Heppner KM, Tschop MH. The role of gherlino in the control of energy balance. Handb Exp Pharmacol 2012;209:161-84
14. Rodgers RJ, Tschop MH, Wilding JP. Antiobesity drugs: past, present and future. Dis Model Mech 2012;5:621-6
15. Erdie-Lalena CR, Holm VA, Kelly PC, et al. Ghrelin levels in youg children with Prader-Willi syndrome. J Pediatr 2006;149:199-204
16. Cummings DE, Clement K, Purnell JQ, et al. Elevated ghrelin levels in Prader-Willi syndrome. Nat Med 2002;8:643-4
17. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric by-pass surgery. N Engl J Med 2002;346:1623-30
18. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002;418:650-4
19. Batterham RL, Fytche DH, Rosenthal JM, et al. PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans. Nature 2007;450:106-9
20. Schwartz MW. Biomedicine. Staying slim with insulin in mind. Science 2000;289:2066-7
21. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-32
22. Friedman JM. Leptin at 14 y of age: an ongoing story. Am J Clin Nutr 2009;89:973-9
23. Farooqi IS, Jebb SA, Langmack G, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999;34:879-84
24. Farooqi IS, Keogh JM, Kamath S, et al. Partial leptin deficiency and human adiposity. Nature 2001;414:34-5
25. Minokoshi Y, Kim Y-B, Peroni OD, et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002;415:339-43
26. Speliotes EK, Willer CJ, Berndt SI, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nature Genet 2010;42:937-48
27. Morton GJ, Cummings DE, Baskin DG, et al. Central nervous system control of food intake and body weight. Nature 2006;443:289-95
28. Available from: http://www.accessdata. fda.gov/scripts/cder/drugsatfda/ index.cfm? fuseaction=Search.DrugDetails
29. Weibel EK, Hadvary P, Hochuly E, Lengsfeld H. Lipstatin, an inhibitor of pancreatic lipase, produced by streptomyces toxytricini, I: producing organism, fermentation, isolation and biological activity. J Antibiot 1987;40:1081-5
30. Rossner S, Sjostrom L, Noack R, et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res 2000;8:49-61
31. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrug SafetyInformationforPatientsand Providers/ucm213038.htm
32. Mcnelly W, Goa KL. Sibutramine. A review of its contribution to the management of obesity. Drugs 1998;56:1093-24
33. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrug SafetyInformationforPatientsand Providers/DrugSafetyInformationfor HeathcareProfessionals/ucm198206.htm
34. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrug SafetyInformationforPatientsand Providers/ucm191652.htm
35. Padwal RS, Manjudar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007;369:71-7
36. Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2003;23:146-89
37. Alterio V, Di Fiore A, D'Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev 2012;112:4421-68
38. Supuran CT. Structure-based drug discovery of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2012;27:759-72
39. Fujikawa-Adachi K, Nishimori I, Taguchi T, Onishi S. Human mitochondrial carbonic anhydrase VB. cDNA cloning, mRNA expression, subcellular localization, and mapping to chromosome x. J Biol Chem 1999;274:21228-33
40. Dodgson SJ, Forster RE II, Storey BT, Mela L. Mitochondrial carbonic anhydrase. Proc Natl Acad Sci USA 1980;77:5562-6
41. Dodgson SJ, Forster RE II. Carbonic anhydrase: inhibition results in decreased urea production by hepatocytes. J Appl Physiol 1986;60:646-52
42. Nishimori I, Onishi S. Carbonic anhydrase isozymes in the human pancreas. Dig Liver Dis 2001;33:68-74
43. Shah GN, Hewett-Emmett D, Grubb J, et al. Mitochondrial carbonic anhydrase CA VB: Differences in tissue distribution and pattern of evolution from those of CA VA suggest distinct physiological roles. Proc Natl Acad Sci USA 2000;97:1677-82
44. Gordon A, Price LH. Mood stabilization and weight loss with topiramate. Am J Psychiatry 1999;156:968-9
45. Picard F, Deshaies Y, Lalonde J, et al. Topiramate reduces energy and fat gains in lean (Fa/r) and obese (fa/fa) Zucker rats. Obes Res 2000;8:656-63
46. Dodgson SJ, Cherian K. Mitochondrial carbonic anhydrase is involved in rat renal glucose synthesis. Am J Physiol 1989;257:E791-6
47. Spencer IM, Hargreaves I, Chegwidden WR. Effects of the carbonic anhydrase inhibitor acetazolamide on lipid synthesis in the locust. Biochem Soc Trans 1988;16:973-4
48. Lynch CJ, Fox H, Hazen SA, et al. Role of hepatic carbonic anhydrase in de novo lipogenesis. Biochem J 1995;310:197-202
49. Nishimori I, Vullo D, Innocenti A, et al. Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors. J Med Chem 2005;48:7860-6
50. Dodgson SJ, Shank RP, Maryanoff BE. Topiramate as an Inhibitor of Carbonic Anhydrase Isoenzymes. Epilepsia 2000;41(Suppl I):S35-9
51. Casini A, Antel J, Abbate F, et al. Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. Bioorg Med Chem Lett 2003;13:841-5
52. Vitale RM, Pedone C, Amodeo P, et al. Molecular modeling study for the binding of zonisamide and topiramate to the human mitochondrial carbonic anhydrase isoform VA. Bioorg Med Chem 2007;15:4152-8
53. Najarian T. Combination therapy for effecting weight loss and treating obesity. WO76493; 2000
54. KozachuK WE. Methods of producing weight loss and treatment of obesity. WO03915; 2002
55. Hebebrand J, Antel J, Preuschoff U, et al. Method for locating compounds for the treatment and/or prophylaxis of obesity. WO07821; 2000
56. Schoen U, Waldeck H, Reinecker U, et al. Novel sulfamate compounds for medical use. WO050252; 2009
57. Antel J, Waldeck H, Schoen U, et al. NSulfamoyl-N'-benzopyranpiperidines as inhibitors of carbonic anhydrases. WO054580; 2007
58. Najarian T. Combination therapy for effecting weight loss and treating obesity. US0002462; 2004
59. Najarian T. Combination therapy for effecting weight loss and treating obesity. US0234950; 2006
60. Najarian T. Combination therapy for effecting weight loss and treating obesity. US0234951; 2006
61. Najarian T, Tam PY, Wilson LF. Compositions and methods for treating obesity and related disorders. WO153632; 2008
62. Najarian T, Tam PY, Wilson LF. Escalating dosing regimen for effecting weight loss and treating obesity. US0304785; 2009
63. Najarian T, Tam PY, Wilson LF. Low dose topiramate/phentermine composition and methods and use thereof. US0262535; 2011
64. Aronne LJ. Combination therapies for the treatment of obesity. WO045416; 2010
65. Aronne LJ. Combination therapies for the treatment of obesity. WO009115; 2011
66. Aronne LJ. Combination therapies for the treatment of obesity. WO041632; 2011
67. Heal DJ, Gosden J, Smith SL. What is the prognosis for new centrally-acting anti-obesity drugs? Neuropharmacology 2012;63:132-46
68. Zareba G. Zonisamide: review of its use in epilepsy therapy. Drug Today (Barc.) 2005;41:589-97
69. De Simone G, Di Fiore A, Menchise V, et al. Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg Med Chem Lett 2005;15:2315-20 .
70. Jenning JE. Zonisamide use in eating disorders. US0026977; 2005
71. Gadde MK, Krishnan KR. Methods for treating obesity. US0319036; 2008
72. Gadde MK, Krishnan KR. Methods for treating obesity. US0098289; 2011
73. Hauske JR. CB1 antagonists and inverse agonists. WO017755; 2009
74. Kovacic P, Pozos RS, Somanathan R, et al. Mechanism of mitochondrial uncouplers, inhibitors, and toxins: focus on electron transfer, free radicals, and structure-activity relationships. Current Med Chem 2005;22:2601-23
75. Arechederra RL, Waheed A, Sly WS, et al. Effect of sulfonamides as selective carbonic anhydrase Va and Vb inhibitors on mitochondrial metabolic energy conversion. Bioorg Med Chem 2013;In press
76. Guzel O, Innocenti A, Scozzafava A, et al. Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inhibitors of human mitochondrial isoforms VA and VB. Bioorg Med Chem 2009;17:4894-9
77. Supuran C, Benedini F, Biondi S, Ongini E. Nitrate esters of carbonic anhydrase inhibitors. WO071421; 2008
78. Supuran CT. Carbonic anhydrase inhibitors. Bioorg Med Chem Lett 2010;20:3467-74
79. Hewitson KS, Supuran CT. Carbonic anhydrase inhibitors for treating dandruff and related disorders. WO061185; 2010
80. Supuran CT, Parkkila S. Treatment of mammalian disorders mediated by alpha-carbonic anhydrase isoforms. WO139678; 2010
81. Ebbesen P, Supuran CT, Scozzafava A, et al. Carbonic anhydrase inhibitors. WO098610; 2011
82. Supuran C, Dedhar S, McDonald P, Carta F. Novel sulfonamide compounds for inhibition of metastatic tumor growth. WO021963; 2012
83. Supuran C, Dedhar S, Carta F, et al. Carbonic anhydrase inhibitors with antimetastatic activity. WO070024; 2012
84. Masereel B, Frederick R, Supuran CT. Tetraline sulfonamide derivatives for use in the treatment of proliferative disorders. WO175654; 2012
85. Supuran C, Scozzafava A, Pastorekova S, Pastorek J. CA IX-specific inhibitors. US7829065; 2010
86. Supuran C, Scozzafava A, Pastorekova S, Pastorek J. CA IX-specific inhibitors. US7833734; 2010
87. Supuran C, Scozzafava A, Pastorekova S, Pastorek J. CA IX-specific inhibitors. US7833737; 2010
88. Supuran C, Scozzafava A, Pastorekova S, Pastorek J. CA IX-specific inhibitors. US7833738; 2010
89. Supuran C, Scozzafava A, Pastorekova S, Pastorek J. CA IX-specific inhibitors. US7833739; 2010
90. Supuran C, Scozzafava A, Pastorekova S, Pastorek J. CA IX-specific inhibitors. US7833514; 2010
91. Supuran CT, Scozzafava A, Pettersen EO, et al. Carbonic anhydrase isoform IX inhibitor coated gold nanoparticles and uses thereof. US6125898; 2009
92. Supuran CT, Scozzafava A. Fluorescent sulfonamide derivatives having carbonic anhydrase inhibiting activity and their use as therapeutic and diagnostic agents. WO137092; 2006
93. Supuran CT. Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs 2012;17:11-15
94. Supuran CT, Di Fiore A, De Simone G. Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs 2008;13:383-92
95. Singh S, Supuran CT. QSARs on carbonic anhydrase human mitochondrial isoforms VA and VB inhibitors of some new not yet synthesized, substituted aromatic/heterocyclic sulfonamides as antiobesity agent. J Enzyme Inhib Med Chem 2012;27:666-72
96. Alterio V, Monti SM, Truppo EC, et al. The first example of significant active site reorganization in a carbonic anhydrase-inhibitor adduct: the carbonic anhydrase I-topiramate complex. Org Biomol Chem 2010;8:3528-33
97. Poulsen SA, Wilkinson BL, Innocenti A, et al. Inhibition of human mitochondrial carbonic anhydrases VA and VB with phenyl triazole benzene sulfonamides. Bioorg Med Chem Lett 2008;4624-7